Major Depressive Disorder

Showing NaN - NaN of 62

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

MDD Trial in United States (REL-1017)

Recruiting
  • Major Depressive Disorder
  • Saraland, Alabama
  • +102 more
Jan 18, 2023

MDD Trial in United States (SAGE-217, Placebo)

Completed
  • Major Depressive Disorder
  • Rogers, Arkansas
  • +52 more
Nov 22, 2022

Migraine, MDD Trial in Worldwide (Fremanezumab, Placebo)

Completed
  • Migraine
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +63 more
Dec 7, 2022

MDD Trial in United States (SP-624, Placebo)

Active, not recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +38 more
May 13, 2022

MDD Trial in United States (REL-1017, Placebo)

Recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +52 more
Apr 14, 2022

MDD Trial in Worldwide (SPD489 (Lisdexamfetamine dimesylate) + Antidepressant)

Terminated
  • Major Depressive Disorder
  • SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
  • Birmingham, Alabama
  • +211 more
Jun 9, 2021

MDD Trial in United States (Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + )

Completed
  • Major Depressive Disorder
  • Antidepressant + SPD489 (lisdexamfetamine dimesylate)
  • Antidepressant + placebo
  • Newport Beach, California
  • +14 more
Jun 8, 2021

MDD Trial in United States (CP-601,927, Placebo)

Terminated
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +57 more
Apr 7, 2021

MDD Trial in United States (Vortioxetine, Placebo)

Completed
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +78 more
Dec 16, 2020

MDD Trial in Puerto Rico, United States (AGO178)

Terminated
  • Major Depressive Disorder
  • Birmingham, Alabama
  • +97 more
Dec 16, 2020

MDD Trial in Puerto Rico, United States (Agomelatine (AGO178C), Placebo)

Completed
  • Major Depressive Disorder
  • Agomelatine (AGO178C)
  • Placebo
  • Birmingham, Alabama
  • +44 more
Dec 16, 2020

MDD Trial in United States (agomelatine, )

Completed
  • Major Depressive Disorder
  • Birmingham, Alabama
  • +77 more
Dec 15, 2020

MDD Trial in Worldwide (MIN-117 5.0 mg, MIN-117 2.5 mg, Placebo)

Completed
  • Major Depressive Disorder
  • MIN-117 5.0 mg
  • +2 more
  • Little Rock, Arkansas
  • +46 more
Dec 14, 2020

Depression, MDD Trial in Canada, United States (Levomilnacipran ER, Placebo)

Completed
  • Depression
  • Major Depressive Disorder
  • Levomilnacipran ER
  • Placebo
  • Beverly Hills, California
  • +34 more
Dec 23, 2019

MDD Trial in Puerto Rico, United States (Cariprazine, Antidepressant Therapy (ADT))

Completed
  • Major Depressive Disorder
  • Tucson, Arizona
  • +89 more
Jul 29, 2019

MDD Trial in Worldwide (ALKS 5461, Placebo)

Completed
  • Major Depressive Disorder
  • ALKS 5461
  • Placebo
  • Birmingham, Alabama
  • +43 more
Aug 2, 2019

MDD Trial in Bulgaria, United States (ALKS 5461, Placebo)

Completed
  • Major Depressive Disorder
  • ALKS 5461
  • Placebo
  • Little Rock, Arkansas
  • +57 more
May 31, 2019

MDD Trial in United States (Antidepressant + , Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2

Completed
  • Major Depressive Disorder
  • Antidepressant + placebo
  • +2 more
  • Phoenix, Arizona
  • +40 more
Feb 12, 2019

MDD Trial in Mexico, United States (desvenlafaxine succinate sustained release, fluoxetine, )

Completed
  • Major Depressive Disorder
  • desvenlafaxine succinate sustained release
  • +2 more
  • Dothan, Alabama
  • +42 more
Jan 2, 2019

MDD Trial in Worldwide (ALKS 5461)

Completed
  • Major Depressive Disorder
  • ALKS 5461
  • Birmingham, Alabama
  • +157 more
Nov 21, 2018

MDD Trial in Worldwide (Placebo, Cariprazine)

Completed
  • Major Depressive Disorder
  • Garden Grove, California
  • +71 more
Mar 29, 2018

MDD Trial in Mexico, United States (DVS SR)

Completed
  • Major Depressive Disorder
  • DVS SR
  • Dothan, Alabama
  • +34 more
Dec 16, 2016

MDD Trial in United States (LY2940094, Placebo)

Completed
  • Major Depressive Disorder
  • North Miami, Florida
  • +9 more
Feb 1, 2017

MDD Trial in United States (GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo)

Completed
  • Major Depressive Disorder
  • GLYX-13 5 mg/kg
  • +2 more
  • Birmingham, Alabama
  • +25 more
Feb 18, 2016

MDD, Irritability Trial in United States (Brexpiprazole)

Completed
  • Major Depressive Disorder
  • Irritability
  • Tucson, Arizona
  • +14 more
Feb 16, 2016